針對(duì)特定疾病的分子亞型的癌癥療法能幫助醫(yī)生調(diào)整治療病人的個(gè)性化治療,。但科學(xué)家們發(fā)現(xiàn),，許多類型的癌癥分子亞型比以前認(rèn)為的那樣更加多樣化，包含進(jìn)一步的遺傳改變,，這些變化可以影響病人的治療反應(yīng),。
以UNC為首的科學(xué)家小組首次證明患者有遺傳變異導(dǎo)致的肺癌分子亞型會(huì)對(duì)對(duì)治療有不同反應(yīng)。這些研究結(jié)果是基于臨床前模型和患者的腫瘤樣本得來的,，研究總結(jié)了三個(gè)非小細(xì)胞肺癌的分子亞型,，并改進(jìn)了對(duì)腫瘤亞型的分子分析。
他們的研究結(jié)果發(fā)表在5月10日,，2012年公共科學(xué)圖書館的網(wǎng)絡(luò)版,。
該研究團(tuán)隊(duì)在2006年首次確定和報(bào)告了三個(gè)肺癌分子亞型，并命名為 Bronchoid 腺癌,，鱗狀癌和Magnoid亞型,。
發(fā)表在PLoS One雜志上的論文中，研究人員試圖確定發(fā)生在每一個(gè)具體的分子亞型中的不同基因突變,。他們發(fā)現(xiàn)各亞型都會(huì)發(fā)生特定的基因突變,，這些突變可能是治療結(jié)合獨(dú)立的預(yù)測(cè)值。（生物谷：Bioon.com）
doi:10.1371/journal.pone.0036530
PMC:
PMID:
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation
Matthew D. Wilkerson, Xiaoying Yi, Vonn Walter, Ni Zhao, Christopher R. Cabanski, Michele C. Hayward, C. Ryan Miller, Mark A. Socinski, Alden M. Parsons, Leigh B. Thorne, Benjamin E. Haithcock, Nirmal K. Veeramachaneni6, William K. Funkhouser, Scott H. Randell1, Philip S. Bernard, Charles M. Perou, D. Neil Haye*
Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well understood, limiting progress in therapy development and research. LAD intrinsic molecular subtypes are a validated stratification of naturally-occurring gene expression patterns and encompass different functional pathways and patient outcomes. Patients may have incurred different mutations and alterations that led to the different subtypes. We hypothesized that the LAD molecular subtypes co-occur with distinct mutations and alterations in patient tumors.
